Cerebrospinal fluid exchange therapy in diseases of the central nervous system: using biologically enriched artificial CSF

Type: Pharmaceuticals
Sector: Regenerative Medicine - Stem Cell Therapy

Unmet Need
Life expectancy steadily increases, and as a result of it the associated high risk of Alzheimer's disease (AD) and other degenerative diseases such as MS, having a huge impact on the family and a financial burden on society. Still no effective drugs are available and a real breakthrough with an unconventional approach is needed. It becomes more and more clear that targeting a single factor (protein, neurotransmitter, etc) involved in the disease pathogenesis is insufficient for therapy, and it seems that multi-targeting of disease related agents would rather be more successful. Moreover, therapy may be more effective when it is directed to both the elimination of the array of putative pathogenic agents from the CNS and supporting/enrichment of the CNS with neuroprotective agents (“brain washing”). The global Alzheimer's disease market is expected to reach 14.8B USD by 2026 only in the seven major markets with a CAGR of 17.5% between 2016-2026. Sales for disease-modifying therapies inMS are estimated to be over 25B USD by 2026


Anovel approach is proposed as a treatment for patients affected by neurodegenerative diseases: Alzheimer's disease, tauopathies, multiple sclerosis, stroke and others, as well as in psychiatric diseases. We propose here a "CSF exchange therapy" performed byexchanging the patient's CSF, the fluid which is in direct contact with the CNS, with enriched CSF containing beneficial components.


In vitro data showing improvement in toxocity to neurons.

In vivo data showing efficacy in EAE and Alzheimer's disease models.

Competitive advantage
In Alzheimer's disease the currently available treatment isonly symptomatic and with limited effect. In Multiple Sclerosis, theavailable treatments are non-specific and non-disease modifying. Our approach provides a more general holistic way for treatment of neurodegenerative diseases.

Share this page on:

Facebook Twitter Google LinkedIn Email


Prof. Hanna Rosenmann

Contact Info:

Tal Almog